J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal
By Bhanvi Satija and Puyaan Singh (Reuters) -Johnson & Johnson said on Monday it will buy neurological drugmaker ...
J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...
Nature3y
Addressing unmet needs in treating a wide range of neurological disorders
“The company’s current pipeline is evidence of its capability to generate multiple exciting new investigational drugs for patients with severely debilitating neurological disorders.
BioWorld16d
Tenvie Therapeutics launches with focus on neurological diseases
The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.
News Medical11d
Preclinical MRI of neurological diseases from morphological imaging to tissue property mapping
An example of chemical shift imaging of the mouse brain acquired via BioSpec Maxwell ... and neurotransmitter concentrations in neurological disorders. Built upon metabolic signatures, CEST ...
J&J to acquire drugmaker Intra-Cellular Therapies for $14.6 billion
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...
Pharmabiz16d
BlackfinBio acquires Parkinson’s IP patent portfolio from OXB
BlackfinBio acquires Parkinson’s IP patent portfolio from OXB: Sheffield, UK Thursday, January 9, 2025, 17:00 Hrs [IST] BlackfinBio Ltd (BFB), a clinical stage gene therapy comp ...